Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2
BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these patients is limited with the comparison of mRNA-base...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1176168/full |
| _version_ | 1827899039564169216 |
|---|---|
| author | Enikő Szabó Szabolcs Modok Benedek Rónaszéki Anna Faragó Anna Faragó Nikolett Gémes Nikolett Gémes Lajos I. Nagy László Hackler Katalin Farkas Patrícia Neuperger Patrícia Neuperger József Á. Balog Attila Balog László G. Puskás László G. Puskás László G. Puskás Gabor J. Szebeni Gabor J. Szebeni Gabor J. Szebeni |
| author_facet | Enikő Szabó Szabolcs Modok Benedek Rónaszéki Anna Faragó Anna Faragó Nikolett Gémes Nikolett Gémes Lajos I. Nagy László Hackler Katalin Farkas Patrícia Neuperger Patrícia Neuperger József Á. Balog Attila Balog László G. Puskás László G. Puskás László G. Puskás Gabor J. Szebeni Gabor J. Szebeni Gabor J. Szebeni |
| author_sort | Enikő Szabó |
| collection | DOAJ |
| description | BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these patients is limited with the comparison of mRNA-based, vector-based or inactivated virus-based vaccines.MethodsForty-nine HD patients and 46 healthy controls (HCs) were enrolled who received two-doses complete vaccination with BNT162b2, or AZD1222, or BBIBP-CorV, respectively. The antibodies reactive to the receptor binding domain of spike protein of SARS-CoV-2 were assayed by Siemens ADVIA Centaur assay. The reactive cellular immunity was assayed by flow cytometry. The PBMCs were reactivated with SARS-CoV-2 antigens and the production of activation-induced markers (TNF-α, IFN-γ, CD40L) was measured in CD4+ or CD8+ T-cells ex vivo.ResultsThe anti-RBD IgG level was the highest upon BNT162b2 vaccination in HDs (1264 BAU/mL) vs. HCs (1325 BAU/mL) among the studied groups. The BBIBP-CorV vaccination in HDs (339.8 BAU/mL ***p < 0.001) and AZD1222 in HDs (669.9 BAU/mL *p < 0.05) resulted in weaker antibody response vs. BNT162b2 in HCs. The response rate of IgG production of HC vs. HD patients above the diagnostic cut-off value was 100% vs. 72% for the mRNA-based BNT162b2 vaccine; 93% vs. 56% for the vector-based AZD1222, or 69% vs. 33% for the inactivated vaccine BBIBP-CorV, respectively. Cases that underwent the anti-CD20 therapy resulted in significantly weaker (**p < 0.01) anti-RBD IgG level (302 BAU/mL) than without CD20 blocking in the HD group (928 BAU/mL). The response rates of CD4+ TNF-α+, CD4+ IFN-γ+, or CD4+ CD40L+ cases were lower in HDs vs. HCs in all vaccine groups. However, the BBIBP-CorV vaccine resulted the highest CD4+ TNF-α and CD4+ IFN-γ+ T-cell mediated immunity in the HD group.ConclusionWe have demonstrated a significant weaker overall response to vaccines in the immunologically impaired HD population vs. HCs regardless of vaccine type. Although, the humoral immune activity against SARS-CoV-2 can be highly evoked by mRNA-based BNT162b2 vaccination compared to vector-based AZD1222 vaccine, or inactivated virus vaccine BBIBP-CorV, whereas the CD4+ T-cell mediated cellular activity was highest in HDs vaccinated with BBIBP-CorV. |
| first_indexed | 2024-03-12T23:11:33Z |
| format | Article |
| id | doaj.art-70d9f571fefd4dca894e4d98dc1c9c62 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-12T23:11:33Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-70d9f571fefd4dca894e4d98dc1c9c622023-07-18T00:53:57ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-07-011010.3389/fmed.2023.11761681176168Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2Enikő Szabó0Szabolcs Modok1Benedek Rónaszéki2Anna Faragó3Anna Faragó4Nikolett Gémes5Nikolett Gémes6Lajos I. Nagy7László Hackler8Katalin Farkas9Patrícia Neuperger10Patrícia Neuperger11József Á. Balog12Attila Balog13László G. Puskás14László G. Puskás15László G. Puskás16Gabor J. Szebeni17Gabor J. Szebeni18Gabor J. Szebeni19Laboratory of Functional Genomics, Biological Research Centre, Szeged, HungaryDepartment of Medicine, Szent-Györgyi Albert Medical School-University of Szeged, Szeged, HungaryDepartment of Medicine, Szent-Györgyi Albert Medical School-University of Szeged, Szeged, HungaryAvidin Ltd., Szeged, HungaryDoctoral School in Biology, Faculty of Science and Informatics, University of Szeged, Szeged, HungaryLaboratory of Functional Genomics, Biological Research Centre, Szeged, HungaryDoctoral School in Biology, Faculty of Science and Informatics, University of Szeged, Szeged, HungaryAvidin Ltd., Szeged, HungaryAvidin Ltd., Szeged, HungaryAstridBio Technologies Ltd., Szeged, HungaryLaboratory of Functional Genomics, Biological Research Centre, Szeged, HungaryDoctoral School in Biology, Faculty of Science and Informatics, University of Szeged, Szeged, HungaryLaboratory of Functional Genomics, Biological Research Centre, Szeged, HungaryDepartment of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Gyorgyi Health Centre, University of Szeged, Szeged, HungaryLaboratory of Functional Genomics, Biological Research Centre, Szeged, HungaryAvidin Ltd., Szeged, HungaryAvicor Ltd., Szeged, HungaryLaboratory of Functional Genomics, Biological Research Centre, Szeged, HungaryDepartment of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, Szeged, HungaryCS-Smartlab Devices, Kozarmisleny, HungaryBackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these patients is limited with the comparison of mRNA-based, vector-based or inactivated virus-based vaccines.MethodsForty-nine HD patients and 46 healthy controls (HCs) were enrolled who received two-doses complete vaccination with BNT162b2, or AZD1222, or BBIBP-CorV, respectively. The antibodies reactive to the receptor binding domain of spike protein of SARS-CoV-2 were assayed by Siemens ADVIA Centaur assay. The reactive cellular immunity was assayed by flow cytometry. The PBMCs were reactivated with SARS-CoV-2 antigens and the production of activation-induced markers (TNF-α, IFN-γ, CD40L) was measured in CD4+ or CD8+ T-cells ex vivo.ResultsThe anti-RBD IgG level was the highest upon BNT162b2 vaccination in HDs (1264 BAU/mL) vs. HCs (1325 BAU/mL) among the studied groups. The BBIBP-CorV vaccination in HDs (339.8 BAU/mL ***p < 0.001) and AZD1222 in HDs (669.9 BAU/mL *p < 0.05) resulted in weaker antibody response vs. BNT162b2 in HCs. The response rate of IgG production of HC vs. HD patients above the diagnostic cut-off value was 100% vs. 72% for the mRNA-based BNT162b2 vaccine; 93% vs. 56% for the vector-based AZD1222, or 69% vs. 33% for the inactivated vaccine BBIBP-CorV, respectively. Cases that underwent the anti-CD20 therapy resulted in significantly weaker (**p < 0.01) anti-RBD IgG level (302 BAU/mL) than without CD20 blocking in the HD group (928 BAU/mL). The response rates of CD4+ TNF-α+, CD4+ IFN-γ+, or CD4+ CD40L+ cases were lower in HDs vs. HCs in all vaccine groups. However, the BBIBP-CorV vaccine resulted the highest CD4+ TNF-α and CD4+ IFN-γ+ T-cell mediated immunity in the HD group.ConclusionWe have demonstrated a significant weaker overall response to vaccines in the immunologically impaired HD population vs. HCs regardless of vaccine type. Although, the humoral immune activity against SARS-CoV-2 can be highly evoked by mRNA-based BNT162b2 vaccination compared to vector-based AZD1222 vaccine, or inactivated virus vaccine BBIBP-CorV, whereas the CD4+ T-cell mediated cellular activity was highest in HDs vaccinated with BBIBP-CorV.https://www.frontiersin.org/articles/10.3389/fmed.2023.1176168/fullhematology diseasesSARS-CoV-2 vaccinationBBIBP-CorVAZD1222BNT162b2COVID-19 |
| spellingShingle | Enikő Szabó Szabolcs Modok Benedek Rónaszéki Anna Faragó Anna Faragó Nikolett Gémes Nikolett Gémes Lajos I. Nagy László Hackler Katalin Farkas Patrícia Neuperger Patrícia Neuperger József Á. Balog Attila Balog László G. Puskás László G. Puskás László G. Puskás Gabor J. Szebeni Gabor J. Szebeni Gabor J. Szebeni Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 Frontiers in Medicine hematology diseases SARS-CoV-2 vaccination BBIBP-CorV AZD1222 BNT162b2 COVID-19 |
| title | Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 |
| title_full | Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 |
| title_fullStr | Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 |
| title_full_unstemmed | Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 |
| title_short | Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 |
| title_sort | comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with bbibp corv or azd1222 or bnt162b2 vaccines against sars cov 2 |
| topic | hematology diseases SARS-CoV-2 vaccination BBIBP-CorV AZD1222 BNT162b2 COVID-19 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1176168/full |
| work_keys_str_mv | AT enikoszabo comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT szabolcsmodok comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT benedekronaszeki comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT annafarago comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT annafarago comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT nikolettgemes comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT nikolettgemes comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT lajosinagy comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT laszlohackler comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT katalinfarkas comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT patricianeuperger comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT patricianeuperger comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT jozsefabalog comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT attilabalog comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT laszlogpuskas comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT laszlogpuskas comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT laszlogpuskas comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT gaborjszebeni comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT gaborjszebeni comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 AT gaborjszebeni comparisonofhumoralandcellularimmuneresponsesinhematologicdiseasesfollowingcompletedvaccinationprotocolwithbbibpcorvorazd1222orbnt162b2vaccinesagainstsarscov2 |